Vedolizumab And Infliximab In The Treatment Of Ulcerative Colitis:Clinical Efficacy Analysis

Objective: To compare the clinical efficacy of Vedolizumab and Infliximab in the treatment of severe ulcerative colitis.Methods: A total of 46 patients diagnosed with ulcerative colitis and treated with biological agents from January 2020 to December 2022 in the Second Department of Digestive Diseases of the First Affiliated Hospital of Xinjiang Medical University were collected,including 16 cases of Infliximab and 30 cases of Vedolizumab.Retrospective analysis was performed on clinical relevant indicators of patients.Results: There was no significant difference between the two groups in terms of gender,age,age of onset,BMI index,lesion range and disease activity(P>0.05);In the Infliximab group,abdominal pain,diarrhea and bleeding decreased compared with before treatment at 14 weeks(P<0.05),C-reactive protein,platelets and white blood cell levels decreased compared with before treatment(P<0.05),albumin and hemoglobin levels increased compared with before treatment(P<0.05),Mayo score and Mayo endoscopic score decreased compared with before treatment(P<0.05),13 patients(81.25%)achieved clinical response,4 patients(25%)achieved clinical remission,and 6patients(37.5%)achieved endoscopic remission;In the Vedolizumab group,abdominal pain,diarrhea and bleeding decreased compared with before treatment at 14 weeks(P<0.05),C-reactive protein,platelets and white blood cell levels decreased compared with before treatment(P<0.05),albumin and hemoglobin levels increased compared with before treatment(P<0.05),Mayo score and Mayo endoscopic score decreased compared with before treatment(P<0.05),23 patients(76.67%)achieved clinical response,9patients(30%)achieved clinical remission,and 13 patients(43.33%)achieved endoscopic remission.There was no significant difference between the two groups in terms of clinical response,clinical remission and endoscopic remission at week 14(P>0.05).Conclusion: Vedolizumab and Infliximab have similar clinical efficacy in clinical response,clinical remission and endoscopic remission in the treatment of severe UC.